The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 7 July 2009, www.theannals.com, DOI 10.1345/aph.1M212.
 The Annals of Pharmacotherapy: Vol. 43, No. 7, pp. 1286-1293. DOI 10.1345/aph.1M212
© 2009 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brooks, A. M.
Right arrow Articles by Thacker, S. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brooks, A. M.
Right arrow Articles by Thacker, S. M

NEW DRUG DEVELOPMENTS

Dapagliflozin for the Treatment of Type 2 Diabetes

Amie McCord Brooks, PharmD BCPS

Associate Professor of Pharmacy Practice, St. Louis College of Pharmacy, St. Louis, MO

Stacey M Thacker, PharmD BCPS

Clinical Assistant Professor of Pharmacy Practice, Southern Illinois University at Edwardsville

Reprints: Dr. Brooks, St. Louis College of Pharmacy, 4588 Parkview Place, St. Louis, MO 63110, abrooks{at}stlcop.edu

OBJECTIVE: To review the literature and describe the pharmacology, pharmacokinetics, clinical safety, and efficacy of dapagliflozin, a compound currently in Phase 3 clinical trials.

DATA SOURCES: A search of the literature was conducted via MEDLINE (1995-March 2009) and ClinicalTrials.gov using the search terms dapagliflozin, SGLT2 inhibitor, sodium-glucose co-transport inhibition, and renal glucose reabsorption inhibition. Bibliographies of identified articles were also used to identify useful references.

STUDY SELECTION AND DATA EXTRACTION: All English-language reports evaluating dapagliflozin were included in this review, including abstracts and scientific presentations.

DATA SYNTHESIS: Due to the increasing prevalence of type 2 diabetes, suboptimal management of the associated hyperglycemia, morbidity and mortality associated with the disease, and the limitations of currently available therapies, novel therapeutic strategies are needed for its treatment. Dapagliflozin represents the first selective, sodium-glucose cotransporter 2 inhibitor that functions by regulating renal glucose reabsorption. Clinical trial data are limited, but available evidence supports clinically significant reductions in fasting plasma glucose, postprandial plasma glucose, hemoglobin A1c, and body weight with this agent. In addition, dapagliflozin has demonstrated excellent tolerability with safety data demonstrated in both Phase 1 and Phase 2 studies.

CONCLUSIONS: Dapagliflozin represents the first in a new class of drugs that may represent a promising new option in the treatment of type 2 diabetes. Results of ongoing Phase 3 clinical trials are necessary to demonstrate efficacy and safety of this agent across various patient populations and clinical scenarios.

Key Words: dapagliflozin, SGLT2 inhibitor, sodium-glucose cotransporter inhibition

Published Online, July 7, 2009. www.theannals.com, DOI 10.1345/aph.1M212




homecopy help contact us subscription past issues search current issue
Copyright © 2009 by Harvey Whitney Books Company.